GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. The team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.
GEn1E Lifesciences is a clinical-stage, Phase 2 company focused on accelerating 1st-in-class precision therapies for inflammatory and rare diseases with unprecedented efficiency. Leveraging seed capital, GEn1E has rapidly advanced from early discovery to Phase 2 in just 2.5 years.
GEn1E Lifesciences operates on a scalable drug development model, unlocking a $100 billion+ opportunity by combining team expertise, advanced technology, and targeted therapies.
GEn1E's team comprises experts in drug discovery, clinical trials, and machine learning. The company’s unique approach integrates a rich database of curated data and machine learning models to accelerate the drug development cycle, ensuring efficient and effective treatment solutions for patients with rare and inflammatory diseases.
Membebaskan potensi terapi berbasis DNA dan RNA menggunakan AI
Membuat target yang tidak dapat diobati menjadi masa lalu
AI untuk Kecerdasan Farmasi
Kami menggunakan AI untuk mendesain antibodi untuk penyakit yang sulit diobati
Rasyonel tasarımla kombinasyon terapisi
AI untuk protein fungsional yang disempurnakan
Nomic, Illumina'nın DNA için yaptığı gibi proteinler için de yapıyor
Cara terbaik untuk menjalankan genom sel tunggal
Terapi multi-target untuk mengobati penyakit kompleks
Laboratorium cloud robot untuk ilmu kehidupan.
Cocokkan dengan profesional yang berpikiran sama untuk percakapan 1:1
Beralih dari Kekacauan Slack ke Kejelasan dalam Hitungan Menit
Personalisasi ribuan halaman arahan dalam waktu kurang dari 30 menit
LLM pertama untuk parsing dokumen dengan akurasi dan kecepatan
Asisten AI untuk profesional SaaS
Aplikasi panggilan telepon bertenaga AI dengan terjemahan langsung
Demo interaktif yang menyenangkan yang didukung AI—sekarang tanpa login
Kopilot Grafik Gerak AI
Lepaskan konfeti untuk menghilangkan stres & kecemasan, 100% bebas AI
Pembayaran yang Lancar untuk SaaS